Effectiveness of dose-intensified salvage regimens versus standard-dose chemotherapy for progression-free survival in early progressed follicular lymphoma before autologous stem cell transplantation: a systematic review protocol.

IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES
Felipe Pereira Mesquita, Kelli Borges Dos Santos, Juliana Akie Takahashi, Marina Guimarães Dutra Giffoni Dos Santos, Glauber Felizardo Alvim, Abrahão Elias Hallack Neto
{"title":"Effectiveness of dose-intensified salvage regimens versus standard-dose chemotherapy for progression-free survival in early progressed follicular lymphoma before autologous stem cell transplantation: a systematic review protocol.","authors":"Felipe Pereira Mesquita, Kelli Borges Dos Santos, Juliana Akie Takahashi, Marina Guimarães Dutra Giffoni Dos Santos, Glauber Felizardo Alvim, Abrahão Elias Hallack Neto","doi":"10.11124/JBIES-23-00231","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This review will evaluate the effectiveness of dose-intensified versus standard-dose salvage regimens on progression-free survival in early progressed follicular lymphoma before high-dose chemotherapy and autologous stem cell transplantation.</p><p><strong>Introduction: </strong>Despite the substantial advances in the management of follicular lymphoma, approximately 20% of patients experience progression of the disease within 2 years of induction therapy. These patients have worse outcomes, and autologous stem cell transplantation has been shown to improve outcomes in this context. Little is known about the optimal salvage regimen.</p><p><strong>Inclusion criteria: </strong>Studies must include patients ≥18 years old with early progressed follicular lymphoma who were submitted to autologous stem cell transplantation in subsequent remission. Clinical trials and observational studies will be included.</p><p><strong>Methods: </strong>The search strategy will be carried out in MEDLINE (PubMed), Embase (Periódicos CAPES), Scopus, Web of Science, LiLACS, and the Cochrane Library. No date or language restrictions will be imposed. The recommended JBI approach to critical appraisal, study selection, data extraction, and data synthesis will be used. Studies should score at least 50% in accordance with the critical appraisal tool. Data will be pooled whenever possible using the random effects model. Heterogeneity will be assessed using the standard χ 2 and I2 tests. A funnel plot will be generated to assess publication bias if there are 10 or more studies included in the meta-analysis. The GRADE approach will be used to rate certainty of evidence.</p><p><strong>Review registration: </strong>PROSPERO CRD42022373345.</p>","PeriodicalId":36399,"journal":{"name":"JBI evidence synthesis","volume":" ","pages":"1850-1856"},"PeriodicalIF":1.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JBI evidence synthesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11124/JBIES-23-00231","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This review will evaluate the effectiveness of dose-intensified versus standard-dose salvage regimens on progression-free survival in early progressed follicular lymphoma before high-dose chemotherapy and autologous stem cell transplantation.

Introduction: Despite the substantial advances in the management of follicular lymphoma, approximately 20% of patients experience progression of the disease within 2 years of induction therapy. These patients have worse outcomes, and autologous stem cell transplantation has been shown to improve outcomes in this context. Little is known about the optimal salvage regimen.

Inclusion criteria: Studies must include patients ≥18 years old with early progressed follicular lymphoma who were submitted to autologous stem cell transplantation in subsequent remission. Clinical trials and observational studies will be included.

Methods: The search strategy will be carried out in MEDLINE (PubMed), Embase (Periódicos CAPES), Scopus, Web of Science, LiLACS, and the Cochrane Library. No date or language restrictions will be imposed. The recommended JBI approach to critical appraisal, study selection, data extraction, and data synthesis will be used. Studies should score at least 50% in accordance with the critical appraisal tool. Data will be pooled whenever possible using the random effects model. Heterogeneity will be assessed using the standard χ 2 and I2 tests. A funnel plot will be generated to assess publication bias if there are 10 or more studies included in the meta-analysis. The GRADE approach will be used to rate certainty of evidence.

Review registration: PROSPERO CRD42022373345.

自体干细胞移植前的早期进展滤泡性淋巴瘤中,剂量强化抢救方案与标准剂量化疗对无进展生存期的影响:系统综述方案。
目的:本综述将评估在大剂量化疗和自体干细胞移植前,剂量强化与标准剂量挽救方案对早期进展滤泡性淋巴瘤患者无进展生存期的有效性:尽管滤泡性淋巴瘤的治疗取得了重大进展,但仍有约20%的患者在诱导治疗后2年内病情恶化。这些患者的预后较差,而自体干细胞移植被认为可改善这种情况下的预后。关于最佳挽救方案,人们知之甚少:研究必须包括年龄≥18岁的滤泡性淋巴瘤早期进展患者,他们在随后的缓解期接受了自体干细胞移植。将纳入临床试验和观察性研究:搜索策略将在 MEDLINE (PubMed)、Embase (Periódicos CAPES)、Scopus、Web of Science、LiLACS 和 Cochrane Library 中进行。没有日期或语言限制。将采用 JBI 推荐的方法进行批判性评估、研究选择、数据提取和数据综合。根据批判性评价工具,研究的评分应至少达到 50%。尽可能使用随机效应模型对数据进行汇总。异质性将使用标准的 χ2 和 I2 检验进行评估。如果荟萃分析中包含 10 项或更多研究,则将生成漏斗图以评估发表偏倚。将采用 GRADE 方法对证据的确定性进行评级:系统综述注册编号:PREMCORD42022373345。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JBI evidence synthesis
JBI evidence synthesis Nursing-Nursing (all)
CiteScore
4.50
自引率
3.70%
发文量
218
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信